Cui Huantian, Li Yuting, Cao Min, Liao Jiabao, Liu Xiangguo, Miao Jing, Fu Hui, Song Ruiwen, Wen Weibo, Zhang Zhaiyi, Wang Hongwu
Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China.
College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Pharmacol. 2020 Jun 9;11:858. doi: 10.3389/fphar.2020.00858. eCollection 2020.
Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of , , and in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches.
代谢组学分析已被用于在代谢水平上表征治疗非酒精性脂肪性肝病(NAFLD)药物的作用及机制。荷叶碱是一种源自[植物名称未给出]的活性成分,已被证明对高脂饮食(HFD)诱导的肝脂肪变性模型具有有益作用。然而,荷叶碱代谢物变化对NAFLD的影响尚未阐明。在本研究中,我们使用HFD建立了NAFLD大鼠模型并用荷叶碱进行治疗。研究了脂质含量水平、促炎细胞因子和氧化应激,以评估荷叶碱的治疗效果。此外,使用非靶向代谢组学分析荷叶碱对NAFLD的代谢调节机制。还研究了荷叶碱干预后与代谢途径变化相关的关键酶的基因表达。结果表明,荷叶碱治疗显著降低了NAFLD大鼠模型的体重、血液中的脂质和肝酶水平,并改善了肝脂肪变性。荷叶碱治疗还增加了肝脏中超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)的活性,并降低了丙二醛(MDA)水平。荷叶碱治疗降低了血清白细胞介素(IL)-6、IL-1β和肿瘤坏死因子-α(TNF-α)水平,并上调了肝脏中[基因名称未给出]、[基因名称未给出]和[基因名称未给出]的基因表达。代谢组学分析表明,NAFLD大鼠模型存在代谢紊乱,表现为甘油磷脂、亚油酸、α-亚麻酸、精氨酸和脯氨酸代谢功能障碍。相反,荷叶碱治疗改善了NAFLD大鼠模型的代谢紊乱。荷叶碱治疗还调节了肝脏中与甘油磷脂、亚油酸和α-亚麻酸代谢途径相关的关键酶的基因表达。总之,我们的研究证明了荷叶碱治疗可改善NAFLD大鼠模型的代谢紊乱。我们的研究有助于通过代谢组学分析和实验方法理解治疗复杂疾病药物的作用及机制。